SIZE XSSIZE SMSIZE MDSIZE LG

Best of AC17 Session - Management of Hodgkin Lymphoma Status post Autologous Hematopoietic Stem Cell Transplantation - On-Demand

    • List Price: $35.00
    • Member Price: $25.00

Although aHSCT is the standard of care for patients with relapsed HL, only about 50% of these patients will be cured. Patients who relapse or have progressive disease after aHSCT have a very poor prognosis. This session will focus on risk factors associated with disease relapse following aHSCT and the use of brentuximab vedotin as consolidation treatment in high-risk patients. The use of novel agents such as PD-1 inhibitors in patients who relapse post aHSCT will also be discussed.

 

Content Area: Patient Management & Therapeutics


Product Details:

Management of Hodgkin Lymphoma Status Post Autologous Hematopoietic Stem Cell Transplantation

 

Speaker: Sandra Horowitz, PharmD

 

Learning Objectives:

1.      Identify risk factors associated with relapse after autologous hematopoietic stem cell transplant (aHSCT)...

Show More
There are not any reviews for this product.
Contains 0 items
Subtotal: $0.00